Physician profile
Antoni J Gofron
NPI 1871501593
$4,730.52
in general payments reported to CMS, 2019-2025
26 companies · $894 in 2025
The $894 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $824 · 2020: $244 · 2021: $713 · 2022: $833 · 2023: $725 · 2024: $497 · 2025: $894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,097 · Education: $19.73.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,096.70 |
| Education | $19.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $949.75 | 2019-2025 | Ozempic, Wegovy |
| Sanofi-Aventis U.S. LLC | $557.31 | 2019-2023 | |
| Dexcom, INC. | $431.61 | 2021-2023 | Dexcom G6 Transmitter |
| Medtronic, INC. | $402.75 | 2021-2025 | Minimed 780g |
| Amgen INC. | $399.22 | 2019-2025 | Evenity, Tepezza, Prolia |
| Lilly USA, LLC | $340.24 | 2022-2025 | Zepbound, Mounjaro |
| Abbott Laboratories | $263.30 | 2021-2023 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $240.28 | 2019-2021 | |
| Tandem Diabetes Care, INC. | $159.21 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Amarin Pharma, INC. | $124.99 | 2019 | |
| Sequel Med Tech, LLC | $117.83 | 2025 | Twiist |
| Nestle Healthcare Nutrition INC. | $114.90 | 2023 | |
| Medtronic Minimed, INC. | $103.41 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $97.38 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Amneal Pharmaceuticals LLC | $58.41 | 2019-2023 | Unithroid |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $54.04 | 2025 | Omnipod |
| Recordati_rare_diseases_inc. | $50.69 | 2021-2024 | Signifor Lar, Isturisa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.49 | 2022 | |
| Radius Health, INC. | $38.04 | 2019-2023 | |
| Antares Pharma, INC. | $37.66 | 2019-2025 | Xyosted |
| Amryt Pharma Holdings LTD | $36.64 | 2022-2023 | Mycapssa |
| Astrazeneca Pharmaceuticals LP | $30.99 | 2021 | |
| Ascendis Pharma Endocrinology INC | $24.22 | 2025 | Yorvipath |
| Opko Pharmaceuticals, LLC | $19.73 | 2023 | Rayaldee |
| Tolmar, INC. | $15.91 | 2025 | Jatenzo |
| Ultragenyx Pharmaceutical INC. | $13.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antoni Gofron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.